Ketone Supplementation, Glucose Control, and Cardiovascular Function
- Conditions
- Overweight and ObesityDiabetes Mellitus RiskHyperglycemia, Postprandial
- Interventions
- Dietary Supplement: Exogenous ketone monoester
- Registration Number
- NCT03817749
- Lead Sponsor
- University of British Columbia
- Brief Summary
Post-prandial hyperglycemic excursions induce a cascade of deleterious effects on the body, including increased inflammation, production of reactive oxygen species, and impaired cardiovascular function. Ingestion of an exogenous oral ketone supplement blunts hyperglycemia in response to an oral glucose tolerance test. Accordingly, it is hypothesized that exogenous ketone supplement ingestion prior to a meal could be an effective strategy for blunting postprandial hyperglycemia. Therefore, the purpose of this study is to investigate the effect of short-term (14-days) pre-meal exogenous ketone supplementation on glucose control, cardiovascular function, inflammation, and oxidative stress in individuals at an elevated risk of type 2 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
- Elevated waist circumference (>102 cm for males, >88 cm for females) and/or Obesity (BMI > 30 kg/m2) and/or Diagnoses of prediabetes based on A1C (5.7-6.4%) and/or fasting plasma glucose (5.6-6.9 mmol/l) using ADA criteria
- Competitively trained endurance athlete
- Actively attempting to lose weight
- History of mental illness or existing neurological disease(s)
- Previous cardiovascular events (i.e., heart attack, stroke)
- Diagnoses of diabetes
- Hypoglycemia
- Irritable bowel syndrome or inflammatory bowel disease
- Taking medication that may interfere with insulin sensitivity
- Currently following a ketogenic diet or taking ketone supplements
- Unable to commit for 2 separate 14-day trials and unable to follow a controlled diet
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Exogenous ketone monoester Participants will consume a flavor matched placebo drink and undergo the same procedures described in the Experimental Arm Experimental Exogenous ketone monoester * Participants will consume 20 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period. * Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period. * All meals will be provided throughout the supplementation period * Participants will wear a continuous glucose monitor for 6 consecutive days during the supplementation period.
- Primary Outcome Measures
Name Time Method Glucose control 2 hours after a meal Post-prandial glucose excursions will be measured by continuous glucose monitoring using the iPro2 CGM by Medtronic in both the active and placebo supplement conditions. Post-prandial glucose following breakfast, lunch, and dinner will be averaged together.
- Secondary Outcome Measures
Name Time Method Change from baseline plasma glucose at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Venous blood samples will be taken and plasma glucose will be measured using a hexokinase method.
Change from baseline cognition (executive functions) at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Cognition will be assessed using a customized battery of psychometrically validated tests within the domain of executive functions using the iPad-based app BrainBaseline. The tests will be the Stroop test, task-switching test, digit-symbol substitution test, and the n-back test.
Change from baseline flow mediated dilation at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Vascular function will be assessed by flow mediated dilation of the brachial artery using vascular ultrasound. A cuff will affixed on the forearm, distal to the brachial artery and will be inflated for 5 minutes. Flow mediation dilation will be measured over a 3-minute period following cuff release.
Change from baseline histone acetylation at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Histone H3 acetylation status will be quantified by flow cytometry using conjugated acetyl-histone H3 antibody specific for Lys9 (Pacific Blue 445) and the conjugated acetyl-histone H3 antibody specific for Lys14 (Alexa Fluor 488).
Change from baseline mitochondrial superoxide production at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Oxidative Stress will be measured by mitochondrial superoxide production in blood lymphocytes, monocytes, and neutrophils by flow cytometry using the MitoSOX red assay (ThermoFisher #M36008) and total intracellular ROS via the DCFDA assay (Sigma #D6883)
Change from baseline plasma insulin at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Venous blood samples will be taken and plasma insulin will be measured using a high-sensitivity human insulin ELISA.
Change from baseline plasma free fatty acids at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Venous blood samples will be taken and free fatty acids will be measured by colorimetric assay.
Change from baseline interleukin-1(IL)-1beta at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Mature IL-1beta secretion will be quantified by ELISA run in duplicate
Change from baseline caspase-1 activation at 14 days Day 0 (Pre-intervention) and Day 14 (post-intervention) Caspase-1 activation will be quantified by flow cytometry. The fluorescent inhibitor probe FAM-YVAD-FMK binds covalently to activated caspase-1 and emits at 530nm
Trial Locations
- Locations (1)
University of British Columbia, Okanagan.
🇨🇦Kelowna, British Columbia, Canada